Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors Metastatic to the Liver 1

Interventions

lutetium Lu 177 dotatate 48Everolimus 40Magnetic Resonance Spectroscopy 21lanreotide 17Temozolomide 17gallium Ga 68 dotatate 15Octreotide 15pembrolizumab 13Nivolumab 13surufatinib 12Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11Sunitinib 10pasireotide 9Specimen Handling 9Positron Emission Tomography Computed Tomography 9Lutetium-177 93-Iodobenzylguanidine 9Ga(III)-DOTATOC 8Carboplatin 8telotristat ethyl 6copper dotatate CU-64 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Ipilimumab 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rose Bengal B × NET × Clear all
NCT02693067 2023-02-08

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Provectus Pharmaceuticals

Phase 1 Unknown
12 enrolled
EndocrineNET

Neuroendocrine Tumors Metastatic to the Liver

Data powered by HemOnc (CC BY 4.0) Colophon âš¡